Results 211 to 220 of about 2,298,074 (328)

Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice [PDF]

, 2013
Abdel Salous, Manikandan Panchatcharam, Manjula Sunkara, Paul Müeller, Anping Dong, Yuhuan Wang, Gregory A. Graf, Susan S. Smyth, Andrew J. Morris   +8 more
openalex   +1 more source

Elimination of Incompatible Uses and Structures [PDF]

, 1955
Norton, C. McKim
core   +1 more source

eliminator

Citation: 'eliminator' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.15657 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Validation of a Genetic Risk Score Combined with Clinical Variables for Predicting Pulmonary Fibrosis in early Rheumatoid Arthritis

Arthritis Care &Research, Accepted Article.
Objectives Pulmonary fibrosis (PF) is a severe extra‐articular manifestation of rheumatoid arthritis (RA). The study aimed to externally validate a genetic risk score (GRS) and a combined risk score for predicting the risk of RA‐associated PF in an independent cohort of early‐RA patients. Methods This study utilized an inception cohort of 1118 patients
Mikael Brink, Austin Wheeler, Bryant R. England, Solbritt Rantapää‐Dahlqvist   +3 more
wiley   +1 more source

Legal framework reform imperatives for rabies elimination in Bangladesh. [PDF]

J Virus Erad
Rahman M, Khan AKMD.
europepmc   +1 more source

Nitrate Elimination

Environmental Health Perspectives, 1996
openaire   +2 more sources

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

High serum PFAS levels in a population after exposure through drinking water in western Tokyo, Japan and their half-lives estimation. [PDF]

Environ Health Prev Med
Lyu Z, Harada KH, Sugii Y, Ueda T, Kimura-Kuroda J, Nakachi S.   +5 more
europepmc   +1 more source

Dermatologist’s role in leprosy elimination/post-elimination

Leprosy Review, 2007
R, Ganapati, V V, Pai, R, Rao
openaire   +2 more sources

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, Accepted Article.
Background Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined: 1) associations between economic insecurities and PROs; 2) the impact of screening and addressing economic insecurities during ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source